OPKO Health, Inc. (OPK)
(OPK) Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Investigation of OPKO Health, Inc. and Encourages Investors to Contact the Firm
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of OPKO Health, Inc. ("Opko" or "the Company") (NASDAQ: OPK). The investigation concerns whether Opko and certain of its officers and/or directors have violated federal securities laws.
On March 5, 2020, Opko’s subsidiary Bioreference Laboratories issued a press release stating “that it will offer a test for the novel coronavirus (2019-nCoV)” and “is expecting to receive specimens for testing, and begin to provide testing next week. With an extensive network of patient service centers and a national logistic network, BioReference will provide expanded access to a COVID-19 testing across the United States.” Then, on March 9, 2020, Hindenburg Research stated via Twitter that Opko was “an obvious coronavirus pump,” characterizing the Company’s March 5 press release as “nonsense” and noting that the Company’s Chief Executive Officer Phillip Frost “has been accused by the SEC of engaging in pump and dump schemes in the past.” On this news, OPKO’s stock price fell sharply, damaging investors.
If you are aware of any facts relating to this investigation, or purchased Opko shares, you can assist this investigation by contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.